Press Releases

Cannasat Therapeutics Announces Successful pre-CTA Meeting with Health Canada Regarding CAT 310

Canada Newswire, December 6, 2021

TORONTO – Cannasat Therapeutics Inc. (CTH - TSXV) ("Cannasat") is pleased to announce a successful pre-CTA (“Clinical Trial Application”) meeting with Health Canada for Phase 1 testing of its lead product, CAT 310, a cannabinoid based pharmaceutical product. The purpose of this pre-CTA meeting was to discuss Cannasat’s proposal for a Phase 1 clinical trial in humans for CAT 310 in order to evaluate the product’s safety and pharmacokinetics.

This meeting was held in Ottawa, Canada, on October 4th, 2006. Prior to this meeting, Cannasat submitted a pre-CTA package that included the intended clinical uses, product rationale, pre-clinical pharmacokinetic data, toxicology data, and the proposed Phase 1 protocol for review by the regulator. Health Canada provided feedback on Cannasat's plans and provided Cannasat with additional guidance on the information required for submitting the CTA to Health Canada for final review.

Cannasat is finalizing the formulation of CAT 310 prototypes to be tested in Phase 1. If final formulation data for CAT 310 also satisfies regulatory requirements, Health Canada indicated that it saw no major obstacles for the product to move forward to human testing.

“We are pleased that our pre-CTA package was accepted by the regulator and that our toxicology and proof of concept studies were satisfactory for the submission of a CTA that will be subject to Health Canada review,” said David Hill, Cannasat’s Chief Executive Officer. “This allows us to move on to final prototype development for conducting Phase 1 testing in human subjects. Positive Phase 1 data will be a significant milestone for Cannasat and will mean that the company is one important step closer to developing a product that relieves pain and suffering for many seriously ill patients who currently have few viable options.”



About Cannasat Therapeutics

Cannasat Therapeutics is researching the therapeutic benefits of cannabis and developing new cannabinoid pharmaceutical products. Cannasat is pursuing two complementary business strategies. The first consists of development of novel cannabinoid pharmaceutical products through application of drug delivery technologies to be introduced to the market through the traditional regulatory drug approval process. The second is to promote medicinal cannabis research and education with Cannasat's business partner, Prairie Plant Systems Inc., the only government licensed grower and distributor of medicinal cannabis in Canada.


Contact Information

Cannasat Therapeutics Inc.
Andrew Williams
Vice President, Operations
W: (416) 703-2449 (Ext. 253)
F: (416) 703-8752
[email protected]


The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Horizonatal Rule
About CynapsusLine SeperationAPL-130277 ProductLine SeperationParkinson's DiseaseLine SeperationInvestor RelationsLine SeperationContact & LegalLine Seperation

Copyright 2016, Cynapsus Therapeutics Inc.
All rights reserved.

Traded on